80 related articles for article (PubMed ID: 38657045)
21. MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages.
Dhanasekaran R; Hansen AS; Park J; Lemaitre L; Lai I; Adeniji N; Kuruvilla S; Suresh A; Zhang J; Swamy V; Felsher DW
Cancer Res; 2023 Feb; 83(4):626-640. PubMed ID: 36525476
[TBL] [Abstract][Full Text] [Related]
22. SOX9 Expression Is Superior to Other Stem Cell Markers K19 and EpCAM in Predicting Prognosis in Hepatocellular Carcinoma.
Ruzinova MB; Ma C; Brunt EM; Goss CW; Vachharajani N; Chapman WC; Liu TC
Am J Surg Pathol; 2023 Jan; 47(1):1-11. PubMed ID: 36322988
[TBL] [Abstract][Full Text] [Related]
23. MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling.
Zhou X; Luo J; Xie H; Wei Z; Li T; Liu J; Liao X; Zhu G; Peng T
Cell Death Discov; 2022 Oct; 8(1):418. PubMed ID: 36243809
[TBL] [Abstract][Full Text] [Related]
24. BET bromodomain inhibitors.
Schwalm MP; Knapp S
Curr Opin Chem Biol; 2022 Jun; 68():102148. PubMed ID: 35462054
[TBL] [Abstract][Full Text] [Related]
25. Integrated Analysis Highlights the Immunosuppressive Role of TREM2
Zhou L; Wang M; Guo H; Hou J; Zhang Y; Li M; Wu X; Chen X; Wang L
Front Immunol; 2022; 13():848367. PubMed ID: 35359989
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
Sun EJ; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829868
[TBL] [Abstract][Full Text] [Related]
27. The long journey to bring a Myc inhibitor to the clinic.
Whitfield JR; Soucek L
J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
[TBL] [Abstract][Full Text] [Related]
28. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
29. Occupancy maps of 208 chromatin-associated proteins in one human cell type.
Partridge EC; Chhetri SB; Prokop JW; Ramaker RC; Jansen CS; Goh ST; Mackiewicz M; Newberry KM; Brandsmeier LA; Meadows SK; Messer CL; Hardigan AA; Coppola CJ; Dean EC; Jiang S; Savic D; Mortazavi A; Wold BJ; Myers RM; Mendenhall EM
Nature; 2020 Jul; 583(7818):720-728. PubMed ID: 32728244
[TBL] [Abstract][Full Text] [Related]
30. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies.
Alqahtani A; Khan Z; Alloghbi A; Said Ahmed TS; Ashraf M; Hammouda DM
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450841
[TBL] [Abstract][Full Text] [Related]
32. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
Hou J; Zhang H; Sun B; Karin M
J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
[TBL] [Abstract][Full Text] [Related]
33. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
34. A human liver cell atlas reveals heterogeneity and epithelial progenitors.
Aizarani N; Saviano A; Sagar ; Mailly L; Durand S; Herman JS; Pessaux P; Baumert TF; Grün D
Nature; 2019 Aug; 572(7768):199-204. PubMed ID: 31292543
[TBL] [Abstract][Full Text] [Related]
35. Bromodomains: a new target class for drug development.
Cochran AG; Conery AR; Sims RJ
Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
[TBL] [Abstract][Full Text] [Related]
36. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs.
Liao Y; Wang J; Jaehnig EJ; Shi Z; Zhang B
Nucleic Acids Res; 2019 Jul; 47(W1):W199-W205. PubMed ID: 31114916
[TBL] [Abstract][Full Text] [Related]
37. Determining cell type abundance and expression from bulk tissues with digital cytometry.
Newman AM; Steen CB; Liu CL; Gentles AJ; Chaudhuri AA; Scherer F; Khodadoust MS; Esfahani MS; Luca BA; Steiner D; Diehn M; Alizadeh AA
Nat Biotechnol; 2019 Jul; 37(7):773-782. PubMed ID: 31061481
[TBL] [Abstract][Full Text] [Related]
38. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
[TBL] [Abstract][Full Text] [Related]
39. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y; Ayer DE; Hurlin PJ; Cherniack AD; Eisenman RN; Bernard B; Grandori C;
Cell Syst; 2018 Mar; 6(3):282-300.e2. PubMed ID: 29596783
[TBL] [Abstract][Full Text] [Related]
40. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma.
Song BN; Chu IS
Exp Mol Med; 2018 Jan; 50(1):e418. PubMed ID: 29303511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
